This case was a patent infringement action under the Hatch-Waxman Act in which Daiichi Pharmaceutical sued Apotex for allegedly infringing U.S. Patent No. 5,401,741 on a topical ofloxacin solution for treating ear infections (otopathy) via Apotex's ANDA for a generic version of FLOXIN Otic. Apotex raised defenses including invalidity by anticipation or obviousness, unenforceability due to inequitable conduct, and noninfringement. Following a bench trial, the court found that the '741 patent was valid and enforceable, as Apotex failed to prove anticipation, obviousness, or deceptive intent by clear and convincing evidence, and held that Apotex's ANDA infringed the patent.
The case concerned a petition by the NLRB Regional Director under Section 10(j) of the National Labor Relations Act seeking temporary injunctive relief against Evergreen America Corporation for alleged unfair labor practices during a union organizing drive by Local 1964. The Board claimed Evergreen interrogated employees about union sympathies, threatened reprisals such as plant closure or job loss, and granted wage increases, promotions, and other benefits to erode union support, causing the union to lose a July 2002 election despite having obtained majority authorization cards beforehand. An Administrative Law Judge found the union had attained majority status by June 2002 and that Evergreen committed multiple violations of Sections 8(a)(1) and (3) of the Act. The court exercised jurisdiction to consider temporary relief, including cease-and-desist and bargaining orders, while the Board’s administrative proceedings remained pending, based on the need to prevent irreparable harm to employee rights.
This case was a class action brought by a participant in an employer-sponsored health plan against PCS Health Systems, a pharmaceutical benefits management company, alleging that PCS breached fiduciary duties under ERISA by switching his prescribed drug to one that generated higher rebates and fees for PCS from drug manufacturers. The court granted summary judgment to PCS. The core reasoning was that PCS provided contracted services like claims processing, formulary management, and drug utilization review to the HMO Oxford but lacked discretionary authority or control over plan assets or administration sufficient to qualify as an ERISA fiduciary, with Oxford retaining decision-making power.
This case involves a dispute over reinsurance coverage for Pfizer's liabilities arising from defective Shiley mechanical heart valves implanted in patients, which occasionally fractured and caused injury or death. The plaintiff, as liquidator of insurer Integrity, sued reinsurer General Accident for failing to pay amounts due under the reinsurance agreement, with the core issue being whether coverage under the policies was triggered by injury at the time of valve implantation or only upon actual fracture. The court addressed post-trial motions to exclude expert testimony from both sides regarding the timing and nature of bodily injury. It denied the defendant's motion to exclude Dr. Gilchrist's testimony, denied in part and granted in part the motion regarding Mr. Bado's testimony, and denied the plaintiff's motion to exclude Dr. Haft's testimony, primarily on grounds of relevance, reliability, and compliance with evidentiary rules for expert opinions. The court also determined that a Minnesota Supreme Court decision on similar insurance coverage did not compel a finding that injury occurred at implantation.
This case involved an appeal by Ricardo and JoAnn DeRosa from a bankruptcy court order expunging their proofs of claim against Chiro Plus, Inc. and related consolidated debtors in a Chapter 7 proceeding. The debtors had hired the DeRosas under a verbal agreement to process and collect bills for medical services, with payment due only upon collection, but the trustee objected on grounds that the bills were deemed fraudulent by insurers, the claims' calculations were unclear, and supporting details were missing. The district court affirmed the bankruptcy court's decision, holding that while the DeRosas' initial filings created a presumptively valid claim, the trustee's evidence negated that presumption and the claimants failed to prove their claims' validity by a preponderance of the evidence. The court also rejected the argument that the prevention doctrine excused the collection condition, finding no evidence that the debtors' actions caused the nonpayment since the bills were independently fraudulent and uncollectible. The appeal was resolved under standards of review applying clear error to facts and de novo to legal conclusions.
The case concerns Daiichi's lawsuit against Apotex for alleged willful infringement of U.S. Patent No. 5,401,741 under the Hatch-Waxman Act, after Apotex filed an ANDA seeking approval for a generic ofloxacin otic solution. The patent claims a method of topically administering ofloxacin in a carrier to treat otopathy, including otitis media and otitis externa, with the goal of avoiding ototoxicity and bacterial resistance risks associated with other antibiotics. The opinion addresses claim construction, reviewing the seven patent claims, the specification's description of ear anatomy and infection risks, FDA approval of Daiichi's FLOXIN Otic product, and the applicable legal standards for interpreting terms from the perspective of a person of ordinary skill in the art. Core reasoning centers on using the patent's intrinsic evidence, such as the claims and specification, to define the scope of the invention without extending to unmentioned side effects or additional drugs.
